O. V. Rodina
Research Subjects
O. V. Rodina has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Diana A. Ivanova
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health ; The Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
4 shared publications - Sergey Evgenievich Borisov
Moscow Municipal Scientific Practical Center of Tuberculosis Control
3 shared publications N. V. Litvinova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы
2 shared publications- Yu. Yu. Mitrofanova
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
2 shared publications Ю. Ю. Митрофанова
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы
2 shared publications- Alexey Filippov
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health, 107014 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 13 (3) , 25-36
Antiviral therapy for hepatitis C in patients with tuberculosis
The aim. The study was to evaluate the effectiveness and safety of co-administration of antituberculosis and antiviral therapy (AVT) in patients with coinfection of chronic viral hepatitis C and pulmonary tuberculosis. Materials and methods. The observational study included 52 patients with active tuberculosis (63.5% drug-resistant cases) and chronic viral hepatitis C; 11 of them received a course of antiviral therapy (pan-genotypic regimens), 8 patients – simultaneously with anti-tuberculosis treatment (ATT, regimens without rifampicin), another 3 – before the start of tuberculosis treatment. Results. All 8 patients (100%) who received simultaneous AVT and ATT demonstrated a virological response; 7 days after the start of AVT, a complete normalization of transaminase levels was observed, which made it possible to prescribe an adequate ATT regimen and achieve successful treatment of tuberculosis. Two patients experienced mild adverse reactions, including transient eosinophilia, associated with the use of anti-tuberculosis drugs. After AVT, liver enzyme levels remained normal until completion of anti-tuberculosis treatment; in group without AVT (n = 41), the incidence of drug-induced liver injury was 61.0% (p < 0.001). Conclusion. Co-administration of anti-tuberculosis and antiviral therapy in tuberculosis patients with chronic hepatitis C is safe and effective. Pangenotypic AVT regimens are optimal. It is better to start including anti-tuberculosis drugs from the second week of antiviral treatment.
- 23 January 2026
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 13 (3) , 25-36
Open AccessAntiviral therapy for hepatitis C in patients with tuberculosis
The aim. The study was to evaluate the effectiveness and safety of co-administration of antituberculosis and antiviral therapy (AVT) in patients with coinfection of chronic viral hepatitis C and pulmonary tuberculosis. Materials and methods. The observational study included 52 patients with active tuberculosis (63.5% drug-resistant cases) and chronic viral hepatitis C; 11 of them received a course of antiviral therapy (pan-genotypic regimens), 8 patients – simultaneously with anti-tuberculosis treatment (ATT, regimens without rifampicin), another 3 – before the start of tuberculosis treatment. Results. All 8 patients (100%) who received simultaneous AVT and ATT demonstrated a virological response; 7 days after the start of AVT, a complete normalization of transaminase levels was observed, which made it possible to prescribe an adequate ATT regimen and achieve successful treatment of tuberculosis. Two patients experienced mild adverse reactions, including transient eosinophilia, associated with the use of anti-tuberculosis drugs. After AVT, liver enzyme levels remained normal until completion of anti-tuberculosis treatment; in group without AVT (n = 41), the incidence of drug-induced liver injury was 61.0% (p < 0.001). Conclusion. Co-administration of anti-tuberculosis and antiviral therapy in tuberculosis patients with chronic hepatitis C is safe and effective. Pangenotypic AVT regimens are optimal. It is better to start including anti-tuberculosis drugs from the second week of antiviral treatment.
- Open Access
- 13 August 2023
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 11 (3) , 39-48
Risk factors for cardiotoxic adverse reactions in the treatment of tuberculosis patients with MDR and XDR of the pathogen
Modern treatment regimens for tuberculosis with multiple and broad drug resistance (MDR/XDR) of the pathogen provide for the simultaneous administration of several drugs with a proven cardiotoxic effect in the form of prolongation of the QTc interval and provocation of life-threatening arrhythmias. In conditions of the spread of cardiovascular and other comorbid pathology, it is important to assess the risk of cardiotoxic reactions and ensure the safety of patients during the entire course of treatment. The aim of the study was to assess the degree and risk of prolongation of the QTc interval in tuberculosis patients with MDR/XDR pathogen, including concomitant cardiological pathology, against the background of treatment regimens with the inclusion of bedaquiline.Materials and methods of research. The retrospective study included 185 tuberculosis patients with MDR/XDR of the causative agent: 70 people with cardiovascular pathology (except decompensation of heart failure, bradyarrhythmias, ventricular arrhythmias and QTc prolongation in the anamnesis) and 115 people. without it, who received chemotherapy with the inclusion of bedaquiline and fluoroquinolones. The dynamics of clinical symptoms and ECG were evaluated against the background of treatment. Risk factors for cardiotoxic reactions were determined using the method of multiple logistic regression.The results of the study. Prolongation of the QTc interval was observed in 58 people (31.4%, 95% CI 25.1–38.4%), clinically significant (more than 500 ms, 60 ms or more from the baseline, with ventricular arrhythmia) – 4.3%; bradycardia – 3.8%, cardialgic syndrome – 8.1%. Risk factors for prolongation of the QTc interval were the presence of any cardiovascular disease (OR 2.33, 95% CI 1.23-4.41), simultaneous administration of three or more drugs that can lead to QTc prolongation (OR = 3.31, 95% CI 1.73–6.32), clarithromycin administration (OR = 4.01, 95%CI 1.4710.97), the number of points on the Tisdale scale is more than 6 (OR = 3.42, 95% CI 1.78–6.62).Conclusion. Prolongation of the QTc interval is a common adverse reaction in the treatment of tuberculosis with MDR /XDR pathogen, clinically significant in 4.3% of cases. The use of a standard ECG monitoring scheme is justified; it is necessary to avoid prescribing three or more drugs that affect the QTc interval to patients with any cardiovascular pathology with a Tisdale score of more than 6 points.
- 13 August 2023
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 11 (3) , 39-48
Open AccessRisk factors for cardiotoxic adverse reactions in the treatment of tuberculosis patients with MDR and XDR of the pathogen
Modern treatment regimens for tuberculosis with multiple and broad drug resistance (MDR/XDR) of the pathogen provide for the simultaneous administration of several drugs with a proven cardiotoxic effect in the form of prolongation of the QTc interval and provocation of life-threatening arrhythmias. In conditions of the spread of cardiovascular and other comorbid pathology, it is important to assess the risk of cardiotoxic reactions and ensure the safety of patients during the entire course of treatment. The aim of the study was to assess the degree and risk of prolongation of the QTc interval in tuberculosis patients with MDR/XDR pathogen, including concomitant cardiological pathology, against the background of treatment regimens with the inclusion of bedaquiline.Materials and methods of research. The retrospective study included 185 tuberculosis patients with MDR/XDR of the causative agent: 70 people with cardiovascular pathology (except decompensation of heart failure, bradyarrhythmias, ventricular arrhythmias and QTc prolongation in the anamnesis) and 115 people. without it, who received chemotherapy with the inclusion of bedaquiline and fluoroquinolones. The dynamics of clinical symptoms and ECG were evaluated against the background of treatment. Risk factors for cardiotoxic reactions were determined using the method of multiple logistic regression.The results of the study. Prolongation of the QTc interval was observed in 58 people (31.4%, 95% CI 25.1–38.4%), clinically significant (more than 500 ms, 60 ms or more from the baseline, with ventricular arrhythmia) – 4.3%; bradycardia – 3.8%, cardialgic syndrome – 8.1%. Risk factors for prolongation of the QTc interval were the presence of any cardiovascular disease (OR 2.33, 95% CI 1.23-4.41), simultaneous administration of three or more drugs that can lead to QTc prolongation (OR = 3.31, 95% CI 1.73–6.32), clarithromycin administration (OR = 4.01, 95%CI 1.4710.97), the number of points on the Tisdale scale is more than 6 (OR = 3.42, 95% CI 1.78–6.62).Conclusion. Prolongation of the QTc interval is a common adverse reaction in the treatment of tuberculosis with MDR /XDR pathogen, clinically significant in 4.3% of cases. The use of a standard ECG monitoring scheme is justified; it is necessary to avoid prescribing three or more drugs that affect the QTc interval to patients with any cardiovascular pathology with a Tisdale score of more than 6 points.
- Open Access
- 30 December 2021
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 9 (4) , 32-42
Cost of the Adverse Events of the Various Chemotherapy Regimens for the Multidrug Resistant Tuberculosis
In order to comparatively assess the amount of costs for the relief of the most common adverse reactions (AE) in different treatment regimens of patients with tuberculosis with multiple and broad drug resistance (MDR and XDR) of the causative agent, an analysis of the frequency, spectrum, severity and cost of relief of all AE developed against the background of chemotherapy of 239 tuberculosis patients with MDR, divided into three groups: I – 82 patients treated in 2011-2015 using only anti-tuberculosis drugs (ATD) of the main and reserve series; II – 77 patients in whom, in addition to these ATD, linezolid was included in the treatment regimen; III – 80 patients treated with linezolid and bedaquiline with ATD of the main and reserve series. The cost–effectiveness analysis used to identify the most economically effective chemotherapy regimen.Results. 564 AE episodes were registered in 220 patients (92.1%, 95% CI 87.9–94.9%), without significant intergroup differences (92.7%, 96.1% and 87.5%, respectively, in groups I, II and III, p > 0.05). AE III–IV degrees of severity were observed in 35 patients (14.6%, 95% CI 10.7–19.7%); no significant differences in severity and frequency of individual types of AE were found. The elimination of myelo-, hepato- and cardiotoxic reactions of III-IV severity required the greatest costs. The cost of cupping all AE and the cost-effectiveness ratio were the lowest in group III patients (CER = 28.9 thousand RUB compared to 41.7 thousand rubles and 40.3 thousand rubles in groups I and II, respectively).Conclusion. Тhe use of tuberculosis chemotherapy regimens with MDR /XDR pathogen with the inclusion of bedaquiline and linezolid requires the lowest total costs for the relief of adverse reactions with comparable effectiveness
- 30 December 2021
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 9 (4) , 32-42
Open AccessCost of the Adverse Events of the Various Chemotherapy Regimens for the Multidrug Resistant Tuberculosis
In order to comparatively assess the amount of costs for the relief of the most common adverse reactions (AE) in different treatment regimens of patients with tuberculosis with multiple and broad drug resistance (MDR and XDR) of the causative agent, an analysis of the frequency, spectrum, severity and cost of relief of all AE developed against the background of chemotherapy of 239 tuberculosis patients with MDR, divided into three groups: I – 82 patients treated in 2011-2015 using only anti-tuberculosis drugs (ATD) of the main and reserve series; II – 77 patients in whom, in addition to these ATD, linezolid was included in the treatment regimen; III – 80 patients treated with linezolid and bedaquiline with ATD of the main and reserve series. The cost–effectiveness analysis used to identify the most economically effective chemotherapy regimen.Results. 564 AE episodes were registered in 220 patients (92.1%, 95% CI 87.9–94.9%), without significant intergroup differences (92.7%, 96.1% and 87.5%, respectively, in groups I, II and III, p > 0.05). AE III–IV degrees of severity were observed in 35 patients (14.6%, 95% CI 10.7–19.7%); no significant differences in severity and frequency of individual types of AE were found. The elimination of myelo-, hepato- and cardiotoxic reactions of III-IV severity required the greatest costs. The cost of cupping all AE and the cost-effectiveness ratio were the lowest in group III patients (CER = 28.9 thousand RUB compared to 41.7 thousand rubles and 40.3 thousand rubles in groups I and II, respectively).Conclusion. Тhe use of tuberculosis chemotherapy regimens with MDR /XDR pathogen with the inclusion of bedaquiline and linezolid requires the lowest total costs for the relief of adverse reactions with comparable effectiveness
- Open Access
- 30 March 2021
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 9 (1) , 77-91
Adverse events of chemotherapy in tuberculosis with multidrug resistant mycobacteria
The review presents current information on the prevalence of multidrug-resistant tuberculosis in the world and in Russia, analyzes the literature data on adverse events of its treatment, their frequency and types, methods of prediction and prevention.
- 30 March 2021
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 9 (1) , 77-91
Open AccessAdverse events of chemotherapy in tuberculosis with multidrug resistant mycobacteria
The review presents current information on the prevalence of multidrug-resistant tuberculosis in the world and in Russia, analyzes the literature data on adverse events of its treatment, their frequency and types, methods of prediction and prevention.
- Open Access
- 12 February 2020
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 98 (1) , 5-15
Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019
The objective: safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings.Subjects: Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs.Results. The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.
- 12 February 2020
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 98 (1) , 5-15
Open AccessSafety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019
The objective: safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings.Subjects: Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs.Results. The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA5278
Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens
Background: The new regimens for MDR TB, presented by WHO in 2018, August, are promising, but their feasibility, depended on safety, isn’t tested enough in real-life conditions. Methods: The retrospective/prospective study include 205 pts with pulmonary MDR TB (18-78 y.o., 64.4% male), divided in 3 groups: “classic” optimized basic regimen (OBR) – 80 pts, OBR and 1-2 of the “fifth group drugs” – 51 pts (OBR+) and the “modern regimen”, based on Bdq Lnz Mox/Lev Cycl with 1-2 other second-line drugs (MR – 74 pts). The groups were equal by gender, age and concomitant diseases (about 50% – COPD; gastrointestinal, liver and heart diseases – about 20% each). Patients on MR had longer history of TB (>5 years in 32.4% vs 12,5% on OBR and 19,6% on OBR+) and the higher rate of previously outcome “treatment failure” (34.3% vs 8.8% and 21.6%, accordingly). Results: No differences between 3 regimens were obtained in number of pts both with all adverse events (AE) (OBR – 61.3%, OBR+ – 68.6%, MR – 67.6%, p=0.61) and seriously AE (III-IV): 17.5%, 19.6% and 16.2%, accordingly, p=0.89). The AE spectrum had the minimal variation: allergic reactions were more often (p<0.001) in the OBR+ (47,1%) and MR (39.2%), then in OBR (25.0%), but the hepatotoxicity – in OBR (33.8%, p=0,03), then in OBR+ (21.6%) and MR (23.0%). Chemotherapy was totally interrupted due to the SAE (from 3 days up to 4 weeks) in 13.8% on OBR, 9.8% on BOR+ and 9.5% – MR (p=0.66). Conclusion: Inclusion of the new drugs in MDR TB treatment regimens didn’t increase the number of AE and SAE and didn’t substantially modify or extend the AE/SAE spectrum. So, the new regimen can be widely implemented in the all categories of patients.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA5278
Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens
Background: The new regimens for MDR TB, presented by WHO in 2018, August, are promising, but their feasibility, depended on safety, isn’t tested enough in real-life conditions. Methods: The retrospective/prospective study include 205 pts with pulmonary MDR TB (18-78 y.o., 64.4% male), divided in 3 groups: “classic” optimized basic regimen (OBR) – 80 pts, OBR and 1-2 of the “fifth group drugs” – 51 pts (OBR+) and the “modern regimen”, based on Bdq Lnz Mox/Lev Cycl with 1-2 other second-line drugs (MR – 74 pts). The groups were equal by gender, age and concomitant diseases (about 50% – COPD; gastrointestinal, liver and heart diseases – about 20% each). Patients on MR had longer history of TB (>5 years in 32.4% vs 12,5% on OBR and 19,6% on OBR+) and the higher rate of previously outcome “treatment failure” (34.3% vs 8.8% and 21.6%, accordingly). Results: No differences between 3 regimens were obtained in number of pts both with all adverse events (AE) (OBR – 61.3%, OBR+ – 68.6%, MR – 67.6%, p=0.61) and seriously AE (III-IV): 17.5%, 19.6% and 16.2%, accordingly, p=0.89). The AE spectrum had the minimal variation: allergic reactions were more often (p<0.001) in the OBR+ (47,1%) and MR (39.2%), then in OBR (25.0%), but the hepatotoxicity – in OBR (33.8%, p=0,03), then in OBR+ (21.6%) and MR (23.0%). Chemotherapy was totally interrupted due to the SAE (from 3 days up to 4 weeks) in 13.8% on OBR, 9.8% on BOR+ and 9.5% – MR (p=0.66). Conclusion: Inclusion of the new drugs in MDR TB treatment regimens didn’t increase the number of AE and SAE and didn’t substantially modify or extend the AE/SAE spectrum. So, the new regimen can be widely implemented in the all categories of patients.